Turnstone Biologics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 82

Employees

  • Stock Symbol
  • TSBX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.59
  • (As of Tuesday Closing)

Turnstone Biologics General Information

Description

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 9310 Athena Circle
  • Suite 300, La Jolla
  • San Diego, CA 92037
  • United States
+1 (347) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Turnstone Biologics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.59 $2.53 $1.62 - $13.20 $59.9M 23.1M 146K -$3.55

Turnstone Biologics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (31,043) (46,654)
Revenue 0 19,306 73,300 101,293
EBITDA (72,487) (52,688) (26,792) 35,091
Net Income (74,897) (55,200) (30,834) 33,269
Total Assets 94,390 112,815 114,938 187,244
Total Debt 2,716 3,214 5,166 2,683
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Turnstone Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Turnstone Biologics‘s full profile, request access.

Request a free trial

Turnstone Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure
Biotechnology
San Diego, CA
82 As of 2024
00000
00000 0000-00-00
00000000 00000

000000

se cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Houston, TX
00 As of 0000
00000
00000000000 00000

00000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000000000000
Watertown, MA
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Turnstone Biologics Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alaunos Therapeutics Formerly VC-backed Houston, TX 00 00000 00000000000 00000
Abata Therapeutics Venture Capital-Backed Watertown, MA 00 00000 0000000000 0 00000
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Navrogen Venture Capital-Backed Cheyney, PA 0 00.00 0000000000 0 00.00
You’re viewing 5 of 62 competitors. Get the full list »

Turnstone Biologics Patents

Turnstone Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022311974-A1 Viral vaccine Pending 16-Jul-2021 0000000000
CA-3225113-A1 Viral vaccine Pending 16-Jul-2021 0000000000
EP-4370700-A1 Viral vaccine Pending 16-Jul-2021 0000000000
AU-2021226903-A1 Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof Pending 27-Feb-2020 000000000
EP-4110799-A1 Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof Pending 27-Feb-2020 C07K14/55
To view Turnstone Biologics’s complete patent history, request access »

Turnstone Biologics Executive Team (18)

Name Title Board Seat Contact Info
Sammy Farah Ph.D Chief Executive Officer & Board Member
Venkat Ramanan Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Vijay Chiruvolu Ph.D Chief Technology Officer, Technology
Joseph Campisi Jr. Chief Legal Officer,Senior Vice President & General Counsel
Stewart Abbot Ph.D Chief Scientific Officer
You’re viewing 5 of 18 executive team members. Get the full list »

Turnstone Biologics Board Members (14)

Name Representing Role Since
Bradley Bolzon Ph.D Versant Ventures Board Member 000 0000
Jerel Davis Ph.D Versant Ventures Chairman 000 0000
Kanya Rajangam Ph.D Self Board Member 000 0000
Michael Burgess Ph.D Turnstone Biologics Chief Medical Officer & Board Member 000 0000
Mike Burgess Ph.D Turnstone Biologics Interim Chief Medical Officer, Executive Director & Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Turnstone Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Turnstone Biologics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Myst Therapeutics 20-Jan-2021 0000000000 Biotechnology 00000 000
To view Turnstone Biologics’s complete acquisitions history, request access »

Turnstone Biologics FAQs

  • When was Turnstone Biologics founded?

    Turnstone Biologics was founded in 2014.

  • Who is the founder of Turnstone Biologics?

    David Stojdl Ph.D, Brian Lichty Ph.D, and John Bell Ph.D are the founders of Turnstone Biologics.

  • Who is the CEO of Turnstone Biologics?

    Sammy Farah Ph.D is the CEO of Turnstone Biologics.

  • Where is Turnstone Biologics headquartered?

    Turnstone Biologics is headquartered in San Diego, CA.

  • What is the size of Turnstone Biologics?

    Turnstone Biologics has 82 total employees.

  • What industry is Turnstone Biologics in?

    Turnstone Biologics’s primary industry is Biotechnology.

  • Is Turnstone Biologics a private or public company?

    Turnstone Biologics is a Public company.

  • What is Turnstone Biologics’s stock symbol?

    The ticker symbol for Turnstone Biologics is TSBX.

  • What is the current stock price of Turnstone Biologics?

    As of 16-Jul-2024 the stock price of Turnstone Biologics is $2.59.

  • What is the current market cap of Turnstone Biologics?

    The current market capitalization of Turnstone Biologics is $59.9M.

  • Who are Turnstone Biologics’s competitors?

    Alaunos Therapeutics, Abata Therapeutics, Iovance Biotherapeutics, NexImmune, and Navrogen are some of the 62 competitors of Turnstone Biologics.

  • What is Turnstone Biologics’s annual earnings per share (EPS)?

    Turnstone Biologics’s EPS for 12 months was -$3.55.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »